Search Results

Sensei Biotherapeutics, Inc. today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.

Sensei Biotherapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.

Sensei Biotherapeutics, Inc. today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development’ at the 3rd Annual VISTA Symposium.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Sensei Biotherapeutics, Inc. today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.

Sensei Biotherapeutics, Inc. today announced that Company management will present at the following conferences in February 2024: Oppenheimer’s 34th Annual Healthcare Life Sciences Conference Wednesday, February 14, 2024, at 10:00 a.m. ET.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications.